Tirzepatide Weight Loss Injection Pen by REVITALABS (Mounjaro)

Tirzepatide targets both the GLP-1 and GIP receptors, meaning that as well as slowing stomach emptying and increasing fullness and satiety, it plays an additional role in enhancing the body's ability to use stored fat as energy, and potentially providing broader weight management effects.

• Tirzepatide is taken as a once-weekly, dose-set pen injection.

A trial with 2539 adults found that weekly tirzepatide (5 mg, 10 mg, or 15 mg) over 72 weeks achieved significant weight loss in overweight and obese patients, with a higher percentage achieving 5%, 10%, 15%, and 20% or more weight loss compared to placebo.1

Always read the label and store as instructed.

• Nausea
• Diarrhoea
• Vomiting
• Pancreatitis (rarely)

*If you use this medication please read the patient information leaflet provided with the product for a full list of side effects. If you have any questions feel free to reach out to our team